Abstract Library

#3009 OPERA: Observational Study of Perception of Information and Quality of Life in Patients with Gastroenteropancreatic NeuroEndocrine TumoRs Starting LAnreotide Autogel–Baseline Characteristics

Introduction: Information provided to patients (pts) with neuroendocrine tumors (NETs) about burden and treatment proposed may influence pts’ adherence to treatment, outpatient monitoring and quality of life (QoL), but can also cause anxiety.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Hautefeuille V

Authors: Hautefeuille V, Do Cao C, Coriat R, Dominguez S, Mineur L,

Keywords: Patients’ perception of information, Quality of Life, Lanreotide,

#2730 FOLFIRINEC, A Multi-Center, Randomized, Comparative Phase II Study of FOLFIRINOX vs Platinum-Etoposide as First Line Treatment for Metastatic Neuroendocrine Carcinoma of Gastroenteropancreatic or Unknown Origin, Associated with Molecular Profiling

Introduction: Grade 3 (G3) gastroenteropancreatic (GEP) neuroendocrine carcinoma (NEC) are rare diseases with a poor prognosis. FOLFIRINEC is a multicenter comparative phase II study of mFOLFIRINOX vs platinum-etoposide (PE) as first line treatment for metastatic G3 NEC of GEP or unknown origin.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Hadoux J

Authors: Hadoux J, Afchain P, Walter T, Tougeron D, Hautefeuille V,

Keywords: neuroendocrine carcinoma, gastroenteropancreatic, chemotherapy, FOLFIRINOX, RB,

#2189 Perioperative Chemotherapy in Resectable Neuroendocrine Carcinomas of the Digestive Tract

Introduction: Neuroendocrine carcinomas (NEC), of the digestive tract are rare and aggressive tumours. In localised disease, the treatment is surgery, followed by administration of adjuvant chemotherapy combining etoposide and platinum salts, justified by the high risk of secondary metastasis. No clinical study has proven the benefit of chemotherapy, and recommendations are based on expert consensus.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Pellat A, Walter T, Hautefeuille V, Hentic O, Augustin J,

Keywords: neuroendocrine, carcinoma, chemotherapy, Ki-67,

#1672 PD-L1 Expression and Quantitative Assessment of Tumor-Infiltrating T Cell Subsets in Carcinoid Tumors and Large Cell Neuroendocrine Carcinomas of the Lung

Introduction: Little is known about the expression of PD-L1 an the immune infiltrate in neuroendocrine neoplasms of the lung.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Julien H

Authors: Kossai M, Hadoux J, Louvet E, Sullivan I, Thomas de Montpreville V,

Keywords: PD-L1, lung, neuroendocrine, immune infiltrate.,

#1564 Well Differentiated Pancreatic Neuroendocrine Tumors (WDPNET) G3: Does the Ki67 Really Do It All?

Introduction: WDPNET G3, although not recognized by the 2010 WHO classification are far from exceptional. They also represent a great therapeutic challenge especially since their molecular drivers are unknown.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: JEROME C

Authors: Cros J, Soukeur M, Raffenne J, Florent D, Thomas De Montpreville V,

Keywords: G3 PNET, transcriptomic profiles, NEC,